Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV

MLA

Stephen G Holt, et al. “Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV.” Journal of Renal and Hepatic Disorders, vol. 2, June 2018, pp. 1–5. EBSCOhost, https://doi.org/10.15586/jrenhep.2018.33.

APA

Stephen G Holt, Paul Champion de Crespigny, Nicole Lioufas, & Alan Street. (2018). Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV. Journal of Renal and Hepatic Disorders, 2, 1–5. https://doi.org/10.15586/jrenhep.2018.33

Chicago

Stephen G Holt, Paul Champion de Crespigny, Nicole Lioufas, and Alan Street. 2018. “Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV.” Journal of Renal and Hepatic Disorders 2 (June): 1–5. doi:10.15586/jrenhep.2018.33.